How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 1, 2008, Pages 28.e1-28.e5

  Rizzo, Manfredi ^a   Berneis, Kaspar ^b   Carmina, Enrico ^a   Rini, Giovam Battista ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

atherosclerosis; high density lipoprotein cholesterol; polycystic ovary syndrome; small and dense low density lipoprotein; triglycerides

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; DISEASE SEVERITY; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MOLECULAR SIZE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 37349006884     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.09.014     Document Type: Article

References (25)

1. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 339 (1998) 861-867
2. Lobo R.A., and Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132 (2000) 989-993
3. Guzick D.S. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 89 (2004) 3694-3695
4. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
5. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A., Sheedy P.F., and Fitzpatrick L. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
6. Cussons A.J., Stuckey B.G.A., and Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185 (2006) 227-239
7. Berneis K., Rizzo M., Fruzzetti F., Lazzaroni V., and Carmina E. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 186-189
8. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
9. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
10. Dejager S., Pichard C., Giral P., et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 54 (2001) 455-462
11. Legro R.S., Blanche P., Krauss R.M., and Lobo R.A. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 72 (1999) 990-995
12. Lemieux S., Lewis G.F., Ben-Chetrit A., Steiner G., and Greenblatt E.M. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 84 (1999) 4278-4282
13. Pirwany I.R., Fleming R., Greer I.A., Packard C.J., and Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54 (2001) 447-453
14. Rizzo M., and Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drug Ther 20 (2006) 205-217
15. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
16. Fleming R., Hopkinson Z.E., Wallace A.M., Greer I.A., and Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 87 (2002) 569-574
17. Ng E.H.Y., Wat N.M.S., and Ho P.C. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 16 (2001) 1625-1631
18. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
19. Tarkun I., Cetinarslan B., Turemen E., Sahin T., Canturk Z., and Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 153 (2005) 115-121
20. Lv L., and Liu Y. Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J Huazhong Univ Sci Technolog Med Sci 24 (2004) 480-482
21. Kilicdag E.B., Bagis T., Zeyneloglu H.B., et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20 (2005) 894-899
22. Glueck C.J., Moreira A., Goldenberg N., Sieve L., and Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18 (2003) 1618-1625
23. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death. N Engl J Med 356 (2007) 2457-2471
24. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 24 (2003) 302-312
25. Carmina E., Chu M.C., Longo R.A., Rini G.B., and Lobo R.A. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90 (2005) 2545-2549